Baker Bros. Advisors’s Phaxiam Therapeutics PHXM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2018
Q4
– Sell
-108,597
Closed -$9.31M – 97
2018
Q3
$9.31M Sell
108,597
-200,000
-65% -$20.8M 0.06% 53
2018
Q2
$34.5M Sell
308,597
-410
-0.1% -$77K 0.26% 30
2018
Q1
$64.9M Hold
309,007
– – 0.55% 24
2017
Q4
$68M Buy
+309,007
New +$73M 0.59% 19

Other funds holding PHXM

Baker Bros. Advisors's PHXM Position: Q4 2018 in Review

Baker Bros. Advisors sold out of Phaxiam Therapeutics (PHXM) in Q4 2018, closing a stake of 108,597 shares — an estimated $9.31M sold.

Baker Bros. Advisors first reported a position in PHXM in Q4 2017 and held it in 4 quarters. The position peaked at $68M in Q4 2017. 5 funds tracked by Wall St. Rank hold PHXM as of Q4 2018.

  • Baker Bros. Advisors reported no remaining Phaxiam Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Baker Bros. Advisors sold 108,597 Phaxiam Therapeutics shares in Q4 2018, an estimated $9.31M.
  • Baker Bros. Advisors first reported a position in Phaxiam Therapeutics in Q4 2017 and held it in 4 quarters.
  • Baker Bros. Advisors's Phaxiam Therapeutics position peaked at $68M in Q4 2017.
  • 5 funds tracked by Wall St. Rank held Phaxiam Therapeutics as of Q4 2018.

Based on Baker Bros. Advisors's 13F filing for Q4 2018, filed 13 Feb 2019.